10-Q: AiXin Life International Reports Q1 2024 Results: Revenue Up, Losses Persist Amid Operational Shifts

AiXin Life International saw a revenue increase in Q1 2024, but losses continued due to rising operating costs and expenses.

Summary

• AiXin Life International reported a net loss of $603,600 for the three months ended March 31, 2024, compared to a net loss of $529,784 for the same period in 2023.
• Total revenue increased by 13% to $851,559, driven by growth in direct sales, pharmacy sales, and Runcangsheng's manufacturing and sales.
• The company's hotel revenue decreased by 54% due to fewer external guests during the Chinese New Year.
• Operating costs and expenses increased to $1,472,805, primarily due to higher expenses in the hotel and Runcangsheng segments.
• The company's pharmacies segment generated a profit from operations in Q1 2024.
• The company had a working capital deficit of $4,250,016 as of March 31, 2024.
• Management acknowledges a material weakness in internal control over financial reporting due to limited resources and absence of financial expertise.
• The company is exploring opportunities to expand its product line, acquire additional pharmacies, and operate nursing homes and clinics.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While revenue increased, the net loss also increased, and the company acknowledges a material weakness in internal control. The company's future plans offer some optimism, but the current financial situation and risks weigh negatively.

Positives

• Total revenue increased by 13% to $851,559 in Q1 2024.
• The pharmacies segment generated a profit from operations in Q1 2024.
• Direct product sales increased by 2% compared to the same period last year.
• Cost of goods sold for direct product sales decreased due to the elimination of a commission program.
• Cost of goods sold at pharmacies decreased due to bulk purchasing and vendor review.

Negatives

• Net loss increased to $603,600 in Q1 2024 from $529,784 in Q1 2023.
• Hotel revenue decreased by 54% due to fewer external guests during the Chinese New Year.
• The company had a working capital deficit of $4,250,016 as of March 31, 2024.
• Management acknowledges a material weakness in internal control over financial reporting.

Risks

• The company's liquidity may be adversely impacted by global events such as health crises, war in Ukraine, conflict in Palestine, and tensions between the United States and China.
• The company's operations are subject to political, economic, and legal risks associated with operating in the PRC.
• The company acknowledges a material weakness in internal control over financial reporting.
• The company may require additional capital to achieve its operational goals and business plans.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders.

Future Outlook

The company intends to look for additional opportunities to profit from the growing healthcare market in China, including expanding its product line, acquiring additional pharmacies, and operating nursing homes and clinics.

Management Comments

• Management acknowledges a material weakness in internal control over financial reporting due to limited resources and absence of financial expertise.
• Management plans to designate individuals responsible for identifying reportable developments and to implement procedures designed to remediate the material weakness.

Industry Context

The company operates in the growing health and wellness market in China, which is driven by the increasing middle class and evolving lifestyles.

Comparison to Industry Standards

• It is difficult to compare AiXin Life International directly to industry standards due to its unique combination of nutritional products, pharmacies, and hotel operations.
• However, the company's revenue growth in the nutritional products and pharmacy segments can be compared to other companies in the health and wellness industry in China, such as By-Health Co., Ltd. and China Traditional Chinese Medicine Holdings Co. Ltd.
• The company's hotel operations can be compared to other hotels in the Chengdu area, but the impact of the Chinese New Year on hotel revenue is a common factor across the industry.

Legal Proceedings

• The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.
• In October 2020, Jian Yiao (the Plaintiff) filed a complaint against Chengdu Aixintang Pharmacy Co., Ltd. (Aixintang Pharmacy, or the Defendant) in Zhangjiagang Peoples Court in Jiangsu Province.

Related Party Transactions

• The company has accounts receivable and sales revenue transactions with related parties, including Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd and Chengdu Aixin International Travel Service Co., Ltd.
• The company has prepaid expenses with Chengdu Aixin International Travel Service Co., Ltd.
• The company has due from and due to related party transactions with various entities and individuals controlled by Mr. Quanzhong Lin.
• The company leases office space from its major shareholder and the wife of a director.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss and the material weakness in internal control.
• Employees may be affected by the company's cost reduction measures and potential changes in operations.
• Customers may benefit from the company's efforts to expand its product line and improve customer service.
• Suppliers may be affected by the company's vendor review and potential changes in purchasing practices.

Next Steps

• The company plans to designate individuals responsible for identifying reportable developments and to implement procedures designed to remediate the material weakness in internal control.
• The company intends to explore opportunities to expand its product line, acquire additional pharmacies, and operate nursing homes and clinics.

Key Dates

Keywords

financial results, quarterly report, pharmacies, hotel, revenue, net loss, operating costs, China, AiXin Life International